RT Journal Article
SR Electronic
T1 Graves’ disease following administration of second dose of SARS-CoV-2 vaccine
JF BMJ Case Reports
JO BMJ Case Reports
FD BMJ Publishing Group Ltd
SP e246432
DO 10.1136/bcr-2021-246432
VO 14
IS 12
A1 Timothy James Goblirsch
A1 Ambika E Paulson
A1 Gerti Tashko
A1 Asefa Jejaw Mekonnen
YR 2021
UL http://casereports.bmj.com/content/14/12/e246432.abstract
AB The SARS-CoV-2 vaccines have had an overwhelming success in curbing the COVID-19 global pandemic, accounting for countless lives saved. Adverse reactions are inevitable, given the vast scale of vaccination required to mitigate future surges of COVID-19. Hyperthyroid disorders have been reported as potential adverse reactions to SARS-CoV-2 vaccines in two patients with Graves’ disease and a group of adults with subacute thyroiditis occurring in young women healthcare workers. We report a case of clinical Graves’ disease in a woman with a previously stable multinodular goitre that occurred 14 days following her second dose of Pfizer-BioNTech SARS-CoV-2 vaccine.